Pharmacogenetic Response to Chemotherapy Induction for ORL Cancers

Inclusion Criteria: * Squamous cell carcinoma originating in the mouth, oropharynx, larynx or hypopharynx has been histologically documented. * The disease is at one of the following UICC 2002 stages, regardless of ganglion status: T3 MO or T4 MO * Treatment via chemotherapy, radiotherapy or surgery (except for the diagnostic biopsy) has not started * The pluridisciplinary committee as ruled out surgical options for technical or functional reasons * Absence of distant metastases * OMS general health status between 0 and 2 * Patient has given informed consent * Patient is affiliated with a social security system Exclusion Criteria: * Undifferentiated squamous cell carcinomas in the nasopharynx (UCNT) * Another cancer priorly treated with one of the following chemotherapies: Docetaxel, Cisplatin, 5-Fluorouracile * Creatininemia \> 2 mg/dl and/or creatinine clearance \< 60ml/min * Patient under guardianship * Presence of another severe pathology including: * severe or chronic cardiac, renal and/or hepatic insufficiencies * severe medullary hypoplasia * severe autoimmune disease * psychosis or senility